SK bioscience

본문바로가기

KOR ENG

sitemap

PR

SK bioscience company news updates

Press releases

SK bioscience and IDT Biologika Partner on Development and Manufacturing of Drug Product for MSD’s Zaire Ebola Vaccine with an Updated Manufacturing Process

2026.03.23
SK bioscience and IVI Announce Recipients of the 2026 ManHoon Park Award, Including U.S. Professor Orenstein

2026.03.19
SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support

2026.03.18
SK bioscience Hosts Nationwide Forum for Healthcare Professionals to Raise Awareness of Meningococcal Disease

2026.03.12
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union

2026.02.26
SK bioscience Strengthens Global Pandemic Preparedness through Participation in Korea’s “100 Days Mission” Simulation Exercise

2026.02.05
SK bioscience Announces Preliminary FY2025 Results 2.4x Revenue Growth Year-over-Year Driven by IDT Turnaround and Strong Vaccine Sales

2026.02.03
SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute

2026.02.03
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family

2026.01.29
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding

2026.01.22